Gastric cancer prevention strategies: A global perspective
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Gastric cancer (GC) is the fifth most common cancer worldwide, and mortality rates are still high. Primary preventive strategies, aimed to reduce risk factors and promote protective ones, will lead to a decrease in GC incidence. Helicobacter pylori infection is a well‐established carcinogen for GC, and its eradication is recommended as the best strategy for the primary prevention. However, the role of other factors such as lifestyle, diet, and drug use is still under debate in GC carcinogenesis. Unfortunately, most patients with GC are diagnosed at late stages when treatment is often ineffective. Neoplastic transformation of the gastric mucosa is a multistep process, and appropriate diagnosis and management of preneoplastic conditions can reduce GC‐related mortality. Several screening strategies in relation to GC incidence have been proposed in order to detect neoplastic lesions at early stages. The efficacy of screening strategies in reducing GC mortality needs to be confirmed. This review provides an overview of current international guidelines and recent literature on primary and secondary prevention strategies for GC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Cheung, K. S., Chan, E. W., Wong, A. Y. S., Chen, L., Wong, I. C. K., & Leung, W. K. (2018) · Gut · doi:10.1136/gutjnl-2017-314605 · Cited by 455
Uedo, N., Ishihara, R., Iishi, H., Yamamoto, S., Yamamoto, S., Yamada, T., Imanaka, K., Takeuchi, Y., Higashino, K., Ishiguro, S., et al. (2006) · Endoscopy · doi:10.1055/s-2006-944632 · Cited by 385
Bradbury, K. E., Appleby, P. N., & Key, T. J. (2014) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.071357 · Cited by 328
Pimentel-Nunes, P., Libânio, D., Lage, J., Abrantes, D., Coimbra, M., Esposito, G., Hormozdi, D., Pepper, M., Drasovean, S., White, J., et al. (2016) · Endoscopy · doi:10.1055/s-0042-108435 · Cited by 252
Buckland, G., Agudo, A., Luján, L., Jakszyn, P., Bueno-de-Mesquita, H. B., Palli, D., Boeing, H., Carneiro, F., Krogh, V., Sacerdote, C., et al. (2010) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.28209 · Cited by 237
Brusselaers, N., Wahlin, K., Engstrand, L., & Lagergren, J. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-017739 · Cited by 204
Yue, H., Shan, L., & Bin, L. (2018) · Gastric Cancer · doi:10.1007/s10120-018-0812-3 · Cited by 183
Pimentel-Nunes, P., Dinis-Ribeiro, M., Soares, J., Marcos-Pinto, R., Santos, C., Rolanda, C., Bastos, R., Areia, M., Afonso, L., Bergman, J., et al. (2012) · Endoscopy · doi:10.1055/s-0031-1291537 · Cited by 166
Cited by
Chivu-Economescu, M., Necula, L. G., Matei, L., Dragu, D., Bleotu, C., Sorop, A., Herlea, V., Dima, S., Popescu, I., & Diaconu, C. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063214 · Cited by 42
“The high rate of mortality is due to the fact that the majority of GC patients are diagnosed at late stages when treatment is often useless (about 20% of GC patients are diagnosed in early stages in Europe), and the therapeutic approach still consists only of combined chemo-radiation therapy followed by surgical resec…”
BackgroundDevelopment and Validation of a Robust Immune-Related Prognostic Signature for Gastric Cancer
Huo, J., Wu, L., & Zang, Y. (2021) · Journal of Immunology Research · doi:10.1155/2021/5554342 · Cited by 16
Metadata
- Authors
- Eusebi, L. H., Telese, A., Marasco, G., Bazzoli, F., & Zagari, R. M.
- Venue
- Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 2020-03-26
- Volume
- 35
- Issue
- 9
- Pages
- 1495-1502
- ISSN
- 0815-9319 (ISSN-L)
- 1440-1746
- OpenAlex
- W3012148640
- Cited by
- 252
- References
- 9
- FWCI
- 35.12
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.